49 results about "Glandular hyperplasia" patented technology

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a pharmaceutical composition for treating benign prostatic hyperplasia and a preparation method thereof. The composition is prepared from the following medicinal materials in parts by weight: 6 to 8 parts of radix aconiti lateralis preparata, 3 to 5 parts of cortex cinnamomi, 10 to 15 parts of fructus alpiniae oxyphyllae, 10 to 15 parts of fructus psoraleae, 5 to 10 parts of semen myristicae, 5 to 10 parts of ground beeltle, 8 to 12 parts of spina gleditsiae, 10 to 15 parts of radix angelicae sinensis, 8 to 12 parts of radix linderae, 15 to 20 parts of radix rehmanniae praeparata, 10 to 15 parts of fructus corni, 8 to 12 parts of rhizoma anemarrhenae, 15 to 20 parts of radix scrophulariae, 8 to 12 parts of rhizoma alismatis, 5 to 10 parts of radix stephaniae tetrandrae and 10 to 15 parts of radix cyathulae. The invention provides the self-prepared medicine composition for treating the prostatic hyperplasia, the diseases of patients with the prostatic hyperplasia are remarkably improved through the synergistic effect of all the medicines in the composition, and a new traditional Chinese medicine treatment thought is provided for clinical treatment of the BPH disease. According to the traditional Chinese medicine composition, medicine pairs are increased or decreased on the basis of referring to a traditional Chinese medicine classic treatment compound, the unique traditional Chinese medicine composition is finally formed, and all the medicine pairs in the formula cooperate with one another and are indispensable.

This invention relates to the application of ALKBH5 as a target in the preparation of drugs for inhibiting the progression of TNBC, and to the drugs themselves. This application discovers mRNA m 6 The alpha-modifying demethylase ALKBH5 is specifically highly expressed in triple-negative breast cancer (TNC). Using spontaneous TNC models and xenograft tumor models, knockout or knockdown of ALKBH5 significantly inhibited breast hyperplasia and the development of TNC, and promoted tumor differentiation. Simultaneously, the specific inhibitor EN300-14040 of ALKBH5 significantly inhibited the growth of TNC organoids, promoted TNC cell differentiation, and enhanced the sensitivity of TNC organoids to the endocrine drug 4OH-T, exhibiting a synergistic inhibitory effect with 4OH-T. Therefore, ALKBH5 represents a potential novel therapeutic target for TNC, and ALKBH5 inhibitors are a potential new type of drug for the treatment of TNC.

The invention belongs to the technical field of traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition for treating or improving prostate diseases and stomach diseases, a traditional Chinese medicine preparation and a preparation method thereof. The traditional Chinese medicine composition comprises the following raw materials: Chinese lobelia, tripterygium wilfordii, selfheal, dandelion, lophatherum gracile, hydrocotyle verticillata and liquorice. The traditional Chinese medicine composition disclosed by the invention is reasonable in compatibility and synergistic in efficacy, can treat prostate diseases such as chronic prostatitis and benign prostatic hyperplasia and stomach diseases such as chronic gastritis and gastric ulcer at the same time by taking a treatment method of clearing away heat and toxic materials, promoting diuresis and treating stranguria, regulating qi and harmonizing stomach and removing stasis and diminishing swelling, has the advantages of definite curative effect, high safety, low recurrence rate, convenience in taking and the like, and is suitable for clinical popularization.

The application discloses application of a reagent for detecting LRRN3 expression level in preparation of a benign prostatic hyperplasia diagnosis product. It is proved through cell function experiments and animal experiments that overexpression of the LRRN3 gene can inhibit the proliferation of prostate cells, block the cell cycle and promote cell apoptosis, thereby effectively inhibiting the prostatic hyperplasia. The discovery provides a new target and treatment strategy for the treatment of the prostatic hyperplasia, and provides a brand-new thought and method for the treatment of the prostatic hyperplasia. Based on the research results, a gene therapy drug taking the LRRN3 gene as a target can be further developed, for example, a lentivirus vector carrying the LRRN3 gene or other gene delivery systems are constructed and used for the treatment of the prostatic hyperplasia. In addition, the LRRN3 gene can be combined with other treatment methods to improve the treatment effect.

The invention discloses 5 alpha-reductase degradation molecules as well as a preparation method and application thereof, four 5 alpha-reductase degradation molecules can realize thorough removal of zymoprotein by inducing proteasome-dependent degradation of 5 alpha-reductase instead of only inhibiting the activity of the 5 alpha-reductase, so that a more lasting treatment effect is obtained; under the condition of equal dosage, the effect of the 5 alpha-reductase degradation molecule on treating the benign prostatic hyperplasia is superior to that of the traditional inhibitor finasteride; the four kinds of 5 alpha-reductase degrading molecules can effectively degrade 5 alpha-reductase protein and remarkably inhibit development of benign prostatic hyperplasia, have good biological safety and provide new strategies and candidate drugs for treatment of diseases related to 5 alpha-reductase such as benign prostatic hyperplasia, prostatic cancer, androgenetic alopecia and acne.

The invention discloses a traditional Chinese medicine formula for treating hyperplasia of mammary glands and breast cancer and a preparation method thereof. The formula comprises radix paeoniae rubra, pseudo-ginseng, radix aucklandiae, swim bladder, angelica sinensis, blister beetle, rhizoma atractylodis macrocephalae and scorpion which are compatible according to a specific proportion. The preparation method comprises the following steps: adding water to soak the five medicinal materials such as red paeony root (1 hour in summer and 2 hours in winter), adding the swim bladder, decocting until the liquid medicine is sticky, grinding the baked cantharides and scorpion into powder, and mixing. Based on theories such as the holism concept of traditional Chinese medicine, multiple modules take effect synergistically, microcirculation can be improved, immunity can be enhanced, cancer cell apoptosis can be induced, the total effective rate for hyperplasia of mammary glands is 96.7%, and the total effective rate for I-II stage breast cancer reaches 86.7%. The traditional Chinese medicine is flexible to take, high in safety and suitable for long-term treatment.

The invention discloses a mammary gland hyperplasia therapeutic instrument, and belongs to the field of mammary gland therapeutic instruments. A mammary gland hyperplasia therapeutic apparatus comprises a machine body and an ultrasonic treatment head, the ultrasonic treatment head is electrically connected with the machine body, a support is placed on the machine body, and paired mammary gland covers are arranged on the support; a connecting head is arranged at the top end of the breast cover, a servo motor is connected in the connecting head, a first arc-shaped rod is connected to the driving end of the servo motor, an adjusting sliding hole is formed in the first arc-shaped rod, an adjusting sliding block is slidably connected in the adjusting sliding hole, a connecting rod is connected to the adjusting sliding block, and the connecting rod is connected to the adjusting sliding block. The ultrasonic treatment head is connected to the connecting rod; the servo motor drives the first arc-shaped rod to rotate, the ultrasonic treatment head is attached to the mammary gland, circumferential massage is conducted along the periphery of the mammary gland along with the first arc-shaped rod, and the ultrasonic treatment head does not need to be manually held for a long time.

The invention discloses a preparation method of a fallen fruit extract and application of the fallen fruit extract in prevention or treatment of hyperplasia of mammary glands. The extract is prepared by extracting immature fruits (fallen fruits) of a traditional Chinese medicinal material Citrus chachiensis through a water decoction method. Experiments prove that the dropped fruit extract can significantly reduce the height and diameter of mammary gland tissues of a mammary gland hyperplasia model rat, significantly reduce the thickness of mammary glands, effectively improve abnormal deposition of collagenous fibers around acelles, and reverse typical proliferative pathological changes of the mammary gland tissues. The invention provides a safe and effective new candidate medicine or functional food raw material for prevention and treatment of hyperplasia of mammary glands, realizes high-valued utilization of citrus chachiensis fallen fruit resources, and has a good application prospect.

A method of treating Sebaceous Hyperplasia (SH) using a 1726 nm laser pulse that selectively targets sebum produced by the sebaceous glands.

The invention relates to application of pulsatilla saponin D in preparation of a medicine for preventing or treating human prostatic hyperplasia. The invention shows that the pulsatilla saponin D has an inhibition effect on human prostate cell WPMY-1, HPRF and BPH-1 cell strains, and can cause cell apoptosis to a certain extent, so that the pulsatilla saponin D shows the effect of preventing or treating prostatic hyperplasia.

This invention relates to a novel use of propargylcysteine ​​in the preparation of anti-mastopathy drugs. The invention discovers that S-propargylcysteine ​​can improve E2 / P imbalance by regulating HPO axis function and inhibiting abnormal activation of the GnRH-sex hormone axis; it also reduces the inflammatory microenvironment by inhibiting the release of inflammatory factors; ultimately, it downregulates ER / PR-mediated proliferation signals and inhibits PCNA expression locally in the breast. Through multi-target regulation of neuroendocrine, inflammatory responses, and proliferation-related signaling pathways, it effectively alleviates breast hyperplasia and its associated chronic stress-induced depressive-like behaviors, thus exerting anti-mastopathy and therapeutic effects on breast hyperplasia complicated with depression.

The application discloses application of a reagent for detecting AHSP protein in preparation of a product for diagnosing prostate cancer, and relates to the technical field of biological medicine; through proteomic analysis, ELISA test on urine protein of prostate cancer patients, clear cell renal cell carcinoma patients and normal healthy men, and immunohistochemical analysis on file wax blocks of the prostate cancer patients, normal prostate tissues around the cancer, prostate tissues of prostatic hyperplasia and clear cell renal cell carcinoma tissues, it is found that the AHSP protein has a certain relationship with the occurrence and development of prostate cancer, and can be used for assisting diagnosis of the prostate cancer; and in urine detection, AHSP has higher sensitivity than PSA, and when PSA is negative or serum PSA is low, AHSP can form complementation with ASHP, thereby helping to improve the diagnosis rate and non-invasive screening ability; through research on the relationship between the AHSP protein and the prostate cancer, the diagnosis rate of patients can be improved, non-invasive reexamination after treatment is facilitated, drug use is guided, and the survival rate is improved.

The application discloses an application of a prostate hyperplasia related marker in preparation of a product for detecting prostate hyperplasia, and the prostate hyperplasia related marker is at least one selected from MINP1, ACTBL and APOC4 proteins. In the technical scheme, MINP1, ACTBL and APOC4 are combined as a detection marker for prostate hyperplasia (BPH), so that the complementarity of the three in different stages of diseases can be fully exerted, and the comprehensive performance of the detection product is obviously improved. MINP1 and ACTBL participate in disease progression by regulating prostate cell proliferation and apoptosis, and APOC4 can present significant expression changes in blood cells of early BPH patients, so that BPH disease screening can be accurately performed. When the three are applied in cooperation, early screening of BPH can be realized, and the activity and severity of the lesion can be evaluated, so that a detection system covering the whole process of disease occurrence and development is formed, the limitation of a single marker in the diagnosis dimension is effectively made up, and the comprehensiveness and accuracy of BPH detection are greatly improved.

The invention discloses nucleus eliminating granules which are prepared by the following steps: adding water into 12 medicinal materials, namely selfheal, oyster, kelp, beautiful sweetgum fruit, fructus aurantii, cowherb seed, salvia miltiorrhiza, curcuma zedoary, ligusticum wallichii, white paeony root, corydalis tuber and radix bupleuri, heating, extracting, filtering, concentrating and drying to obtain medicinal powder; and sieving, adding auxiliary materials, adding a wetting agent, preparing a soft material, granulating, and drying to obtain the kernel eliminating granules. The invention further discloses a preparation method of the nucleus eliminating particles, a thin-layer chromatography identification and content determination method and application of the nucleus eliminating particles. According to the invention, the nucleus-eliminating mixture is developed into the nucleus-eliminating particles, the forming rate, the dissolution rate, the moisture absorption rate, the fluidity and the like of the nucleus-eliminating particles all meet the requirements of Chinese Pharmacopoeia, and the stability experiment result shows that the product stability is good; the curative effect of the nucleus eliminating granules on breast pain, breast nodules, hyperplasia of mammary glands and breast diseases can be achieved; doctors realize accurate medication under treatment based on syndrome differentiation, and the flexibility of adjusting prescriptions along with symptoms is guaranteed; on the other hand, more convenient carrying and taking experience can be provided for the patient.

The invention discloses a minimally invasive surgery treatment system for benign prostatic hyperplasia and a use method of the minimally invasive surgery treatment system. The system comprises an outer cannula used for entering the body of a patient through the urethra, a handle connected to the outer cannula, a cannula installed in the outer cannula, a stretching tube installed in the cannula, a guide wire installed in the stretching tube, a puncture needle head installed at the free end of the guide wire, a rotation driving mechanism used for driving the guide wire to rotate and a telescopic driving mechanism used for driving the cannula to move. A plurality of cutting knives which are uniformly arranged around the stretching tube are arranged between the free end of the stretching tube and the puncture needle head; a magnetic ring which is magnetically attracted with the puncture needle head is arranged at the free end of the sleeve; a guide wire locking mechanism used for locking the guide wire and a stretching pipe adjusting and locking mechanism used for adjusting the position of the stretching pipe and locking the stretching pipe are further arranged in the handle. The system is reasonable in structural design, the telescopic cutting knife is integrated into the puncture assembly, when the system is used for operation, trauma is small, recovery is fast, only local anesthesia is needed, the effect is fast, and the operation effect is good.

The application provides application of a CFTR corrector in preparation of a drug for treating mammary gland hyperplasia, and belongs to the field of biopharmacy.The application creatively finds, through non-clinical pharmacodynamics test, that a compound represented by formula I, tizacatol, can significantly reduce the nipple diameter, height and uterus index of a mammary gland hyperplasia rat model, relieve mammary gland hyperplasia, and improve the content level of E2 and PROG in serum, and has a good treatment effect in treating mammary gland hyperplasia, and has the potential of being applied in preparation of a drug for treating mammary gland hyperplasia.

The present invention relates to a pharmaceutical composition, a food composition and a feed composition for preventing, ameliorating or treating benign prostatic hyperplasia, each composition comprising an Alpiniae oxyphyllae Fructus extract, and a method for treating benign prostatic hyperplasia by using the pharmaceutical composition. The pharmaceutical composition, the food composition, and the feed composition exhibit the effect of inhibiting prostatic hypertrophy caused by male hormone imbalance, can reduce lower urinary tract symptoms caused by prostatic hypertrophy by inhibiting prostatic proliferation, and can be developed, through non-clinical and clinical studies, as pharmaceuticals that are effective in preventing and treating benign prostatic hyperplasia, health functional foods and health foods that are beneficial to prostate health, and the like.

The invention discloses application of a prostatic hyperplasia related marker in preparation of a product for detecting prostatic hyperplasia. The prostatic hyperplasia related marker is selected from at least one of MINP1, ACTBL and APOC4 protein. In the technical scheme provided by the invention, MINP1, ACTBL and APOC4 are combined as the BPH detection marker, complementarity of the MINP1, ACTBL and APOC4 in different stages of diseases can be fully exerted, and the comprehensive efficiency of a detection product is remarkably improved. Wherein MINP1 and ACTBL participate in disease progression by regulating prostate cell proliferation and apoptosis, APOC4 can present significant expression change in blood cells of an early-stage BPH patient, and BPH disease screening can be accurately carried out. When the three markers are synergistically applied, early screening of BPH can be realized, lesion activity and severity can be evaluated, a detection system covering the whole course of disease occurrence and development is formed, the limitation of a single marker on the diagnosis dimension is effectively made up, and the comprehensiveness and accuracy of BPH detection are greatly improved.

The invention discloses application of sitagliptin in preparation of a medicine for treating Graves eye diseases, and belongs to the field of biological medicine. The invention discloses the application of sitagliptin in preparation of the medicine for treating Graves eye diseases for the first time, and sitagliptin can improve expression of CD4 + CTL cytotoxic functional molecules and improve eye symptoms, extraocular muscle thickening and fibrosis, orbit fat neogenesis and orbit T lymphocyte infiltration of mice; the mouse spleen CD4 + CTL cell proportion is improved; in addition, the thyroid hormone level, thyroid hyperplasia and hypertrophy and lymphocyte infiltration of mice can be improved. Sitagliptin is a clinically common hypoglycemic drug, and is perfect in safety database, small in side effect and easy to popularize clinically. Therefore, the experimental result of the invention fully supports the new application of sitagliptin in treating Graves eye diseases, and is a new direction worthy of exploration for treating Graves eye diseases due to strong clinical operability.

The invention provides a composition helpful for maintaining prostate health. The composition comprises the following raw materials in parts by weight: 3-5 parts of rape pollen, 0.1-0.5 part of lycopene powder, 0.1-0.2 part of a turmeric ethanol extract, 1-2 parts of a chicory extract, 1-2 parts of a dandelion extract and 1-2 parts of auxiliary materials. The invention also provides a preparation method and application of the composition helpful for maintaining prostate health. According to the invention, the rape pollen, the lycopene powder, the turmeric ethanol extract, the chicory extract and the dandelion extract have a synergistic effect to form a multi-target synergistic effect mechanism of reducing androgen metabolism, preventing inflammatory response and reducing oxidative damage, so that the traditional Chinese medicine composition can prevent and treat prostatic hyperplasia, also has an excellent effect on abacterial prostatitis, and is free of toxic and side effects. And the traditional Chinese medicine composition is safe, efficient and suitable for long-term administration. The invention belongs to the technical field of food and health care product processing.

The invention discloses application of ginseng and antler kidney tonifying tablets in preparation of drugs for preventing and / or treating prostatic hyperplasia. The ginseng antler kidney-tonifying tablet has a good treatment effect on prostatic hyperplasia, the treatment effect is remarkable, no operation is needed, the ginseng antler kidney-tonifying tablet belongs to new use of an old medicine, the safety is high, the side effect is small, and the production cost is greatly reduced. The problems that current western medicines for treating benign prostatic hyperplasia are long in medication cycle, large in toxic and side effects and limited in clinical application are solved. Experimental results show that the ginseng and antler kidney-tonifying tablet can reduce the prostate gland coefficient; the androgen level of a prostatic hyperplasia patient is reduced; the gland and glandular cavity expansion and hyperplasia degree of a prostatic hyperplasia patient is improved.

This invention relates to a urinary catheter for post-prostatectomy, comprising an outer sheath, a catheter disposed inside the outer sheath, and an expansion component disposed on the surface of the outer sheath. Compared with the prior art, this invention, through the protruding structure on the surface of the balloon, allows the doctor to achieve hemostasis on the wound after prostatectomy via the balloon. The protruding structure can closely fit the uneven interior of the wound after surgery, resulting in better hemostasis compared to the smooth balloon surface in the prior art. At the same time, since the interior of the protrusion is connected to the interior of the balloon, the expansion size of the protrusion during the balloon inflation phase can be affected by the unevenness of the wound surface, avoiding excessive pressure on the post-operative wound area. In addition, the design of multiple sub-protrusions can increase the contact area after the balloon is filled with water or air, resulting in better compression hemostasis.

This invention relates to the field of pharmaceutical biotechnology, providing the application of aminoquinoline compounds (such as hydroxychloroquine and chloroquine) in the preparation of drugs for treating hyperparathyroidism. These compounds restore the expression of calcium-sensitive receptors (CaSRs) on the cell membrane surface by inhibiting the lysosomal degradation pathway of CaSRs in parathyroid cells. Experiments have confirmed that 4-aminoquinoline compounds, used alone or in combination with calcimimetics (such as cinacalcet), significantly reduce serum PTH and calcium levels in a model of refractory secondary hyperparathyroidism (SHPT) and inhibit glandular hyperplasia. In particular, the combination therapy regimen exhibits a significant synergistic effect, effectively reversing calcimimetics resistance. This invention is the first to discover a novel use for the antimalarial / antirheumatic drug hydroxychloroquine in the treatment of hyperparathyroidism, realizing a new use for an existing drug; and providing a safe and effective new drug treatment strategy for clinically refractory SHPT.

The present invention discloses a method for preventing or treating prostatic hyperplasia. The present invention is the first to discover and verify that rice bran oil has the effect of inhibiting benign prostatic hyperplasia and associated lower urinary tract symptoms.

1. The name of the design product: disposable surgical instruments for treating benign prostatic hyperplasia. 2. The use of the design product: medical instruments for minimally invasive treatment of benign prostatic hyperplasia by condensing steam. 3. The design features of the design product: in shape. 4. The picture or photo that best indicates the design features: perspective view.

A method of treating Sebaceous Hyperplasia (SH) using a 1726 nm laser pulse that selectively targets sebum produced by the sebaceous glands.

The invention discloses a multifunctional radiofrequency ablation catheter for non-invasive treatment of prostatic hyperplasia through urethra and a synergistic device. The multifunctional radiofrequency ablation catheter and the synergistic device integrate the five functions of radiofrequency ablation, circulating cooling, catheterization flushing, balloon fixing and temperature sensing. The radiofrequency ablation system is composed of a radiofrequency generator, a circular-tube-shaped radiofrequency ablation electrode and a dispersion electrode. The cooling system is composed of a double-channel cooling circulation pipeline, an embedded temperature sensor, a peristaltic pump and a cold constant-temperature water tank. The urethral catheterization system comprises a drainage tube cavity, a flushing tube cavity, a balloon tube cavity and a front-end expandable balloon. The in-vitro control system is composed of an integrated multi-parameter monitoring module, a control panel and a data record. Based on the unique cognition that the radio frequency ablation metal electrode does not produce heat, precise ablation and catheterization flushing of hyperplastic prostate tissue are synchronously achieved through urethral intervention. The non-invasive radio frequency energy control and cooling technology can effectively protect the urethral mucosa, and has the advantages of efficient treatment, safe operation and rapid recovery.

This invention discloses a treatment device for benign prostatic hyperplasia that utilizes an anchor assembly and a needle. [Solution] The prostate enlargement treatment device according to the present invention includes a plurality of anchors positioned outside the prostate to compress the urethra, and a ligature that connects the plurality of anchors to each other so that the plurality of anchors continuously compress the prostate tissue to secure the prostatic urethra. The device may further include an elastic needle that houses the anchors and the ligature and guides them into the urethra so that they are placed in the prostate, and a needle launching means that launches the needle so that it is inserted into the urethra and is operated so that the plurality of anchors and the ligature are discharged through the needle.

The invention discloses a siRNA preparation for treating benign prostatic hyperplasia, and belongs to the technical field of biological pharmacy. By analyzing mRNA sequences of human and rat SRD5A2, two siRNA sequences for silencing SRD5A2 protein expression are designed and synthesized. The two kinds of siRNA transfect human normal prostate matrix immortalized cells through lipidosome, and both siRNA-1 and siRNA-2 can achieve a good SRD5A2 gene silencing effect. Two siRNA-liposome compounds are intravenously injected into a benign prostatic hyperplasia model rat induced by testosterone propionate, and the siRNA-1 and the siRNA-2 can effectively silence the expression of the SRD5A2 in the rat body. After a prostatic hyperplasia model rat is treated by the two siRNAs, the content of dihydrotestosterone DHT in serum is remarkably reduced compared with that of an untreated model group, and the prostate index is also remarkably reduced.

The invention discloses an external black plaster for treating soft tissue pain and osteoarticular diseases as well as a preparation method and application of the external black plaster. The black plaster is prepared from fineleaf schizonepeta herb, divaricate saposhnikovia root, garden balsam stem, dahurian angelica root, safflower, medicinal cyathula root, red peony root, Chinese angelica, dried orange peel, frankincense, myrrh, common duckweed herb, dried river shrimp, minium and sesame oil according to a specific ratio. The preparation method comprises the steps of material frying, oil refining, pellet feeding, fire toxin removing, spreading and the like. Based on the theory of treating different diseases at the same time in traditional Chinese medicine, aiming at the core pathogenesis of qi stagnation, blood stasis and meridian obstruction, the traditional Chinese medicine composition is scientific in formula and has the effects of promoting blood circulation to remove blood stasis, relieving swelling and pain, dispelling wind and eliminating dampness and clearing and activating the channels and collaterals. Clinical application proves that the plaster has remarkable curative effects on soft tissue pain such as mastitis and hyperplasia of mammary glands and osteoarticular diseases such as lumbar disc herniation, arthritis and cervical spondylosis, is safe and convenient to use and has important clinical application value.